JP2001504325A - 回帰的配列シャフリングおよび選択による遺伝子治療の最適化のための方法 - Google Patents

回帰的配列シャフリングおよび選択による遺伝子治療の最適化のための方法

Info

Publication number: JP2001504325A
Authority: JP; Japan
Prior art keywords: cells; virus; recombinant; segment; recombination
Prior art date: 1996-09-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP51594198A

Other languages

English (en)

Japanese (ja)

Inventor

ピー．シー．ステンマー，ウィレム

シー．クリスチャンズ，フレデリック

リウ，シ―カウ

Original Assignee

マキシジェン，インコーポレイテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-27

Filing date

1997-09-26

Publication date

2001-04-03

1997-09-26 Application filed by マキシジェン，インコーポレイテッド filed Critical マキシジェン，インコーポレイテッド

2001-04-03 Publication of JP2001504325A publication Critical patent/JP2001504325A/ja

Status Pending legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 137
238000001415 gene therapy Methods 0.000 title claims abstract description 97
238000005457 optimization Methods 0.000 title description 2
108090000623 proteins and genes Proteins 0.000 claims abstract description 234
239000013598 vector Substances 0.000 claims abstract description 222
108020004414 DNA Proteins 0.000 claims abstract description 118
230000014509 gene expression Effects 0.000 claims abstract description 92
230000001976 improved effect Effects 0.000 claims abstract description 91
150000007523 nucleic acids Chemical class 0.000 claims abstract description 74
230000003612 virological effect Effects 0.000 claims abstract description 72
102000039446 nucleic acids Human genes 0.000 claims abstract description 58
108020004707 nucleic acids Proteins 0.000 claims abstract description 58
230000001965 increasing effect Effects 0.000 claims abstract description 39
239000013603 viral vector Substances 0.000 claims abstract description 35
230000005847 immunogenicity Effects 0.000 claims abstract description 12
230000006798 recombination Effects 0.000 claims description 232
238000005215 recombination Methods 0.000 claims description 232
241000700605 Viruses Species 0.000 claims description 216
238000012216 screening Methods 0.000 claims description 72
102000004169 proteins and genes Human genes 0.000 claims description 70
239000012634 fragment Substances 0.000 claims description 57
238000001727 in vivo Methods 0.000 claims description 52
238000000338 in vitro Methods 0.000 claims description 51
238000004806 packaging method and process Methods 0.000 claims description 31
230000006872 improvement Effects 0.000 claims description 26
125000003729 nucleotide group Chemical group 0.000 claims description 17
230000002829 reductive effect Effects 0.000 claims description 17
239000002773 nucleotide Substances 0.000 claims description 15
108020005202 Viral DNA Proteins 0.000 claims description 10
230000008569 process Effects 0.000 claims description 10
108010067390 Viral Proteins Proteins 0.000 claims description 8
238000002744 homologous recombination Methods 0.000 claims description 8
230000006801 homologous recombination Effects 0.000 claims description 8
108090000765 processed proteins & peptides Proteins 0.000 claims description 8
231100000419 toxicity Toxicity 0.000 claims description 8
230000001988 toxicity Effects 0.000 claims description 8
238000001890 transfection Methods 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 6
230000002147 killing effect Effects 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 5
230000000368 destabilizing effect Effects 0.000 claims description 4
230000008030 elimination Effects 0.000 claims description 4
238000003379 elimination reaction Methods 0.000 claims description 4
102000004196 processed proteins & peptides Human genes 0.000 claims description 4
230000009261 transgenic effect Effects 0.000 claims description 4
108010053187 Diphtheria Toxin Proteins 0.000 claims description 3
102000016607 Diphtheria Toxin Human genes 0.000 claims description 3
108020004440 Thymidine kinase Proteins 0.000 claims description 3
231100000518 lethal Toxicity 0.000 claims description 3
230000001665 lethal effect Effects 0.000 claims description 3
229920001184 polypeptide Polymers 0.000 claims description 3
230000001131 transforming effect Effects 0.000 claims description 3
102000006601 Thymidine Kinase Human genes 0.000 claims description 2
231100000225 lethality Toxicity 0.000 claims 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
239000004472 Lysine Substances 0.000 claims 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
231100001160 nonlethal Toxicity 0.000 claims 1
241000701161 unidentified adenovirus Species 0.000 abstract description 46
230000010354 integration Effects 0.000 abstract description 42
208000015181 infectious disease Diseases 0.000 abstract description 31
230000010076 replication Effects 0.000 abstract description 24
102000053602 DNA Human genes 0.000 abstract description 22
108020004682 Single-Stranded DNA Proteins 0.000 abstract description 7
241000702371 Enterobacteria phage f1 Species 0.000 abstract description 5
230000000813 microbial effect Effects 0.000 abstract description 5
230000014759 maintenance of location Effects 0.000 abstract description 4
210000004027 cell Anatomy 0.000 description 384
239000000758 substrate Substances 0.000 description 87
239000013612 plasmid Substances 0.000 description 82
235000018102 proteins Nutrition 0.000 description 66
239000000047 product Substances 0.000 description 52
241000282414 Homo sapiens Species 0.000 description 42
229940079593 drug Drugs 0.000 description 36
239000003814 drug Substances 0.000 description 36
108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 description 36
102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 description 35
239000003550 marker Substances 0.000 description 34
230000004048 modification Effects 0.000 description 32
238000012986 modification Methods 0.000 description 32
210000000130 stem cell Anatomy 0.000 description 31
210000001519 tissue Anatomy 0.000 description 30
230000000694 effects Effects 0.000 description 29
230000035772 mutation Effects 0.000 description 29
108091034117 Oligonucleotide Proteins 0.000 description 25
239000003112 inhibitor Substances 0.000 description 23
108010014722 Alkyl and Aryl Transferases Proteins 0.000 description 21
102000002226 Alkyl and Aryl Transferases Human genes 0.000 description 20
230000027455 binding Effects 0.000 description 20
102000052510 DNA-Binding Proteins Human genes 0.000 description 18
206010028980 Neoplasm Diseases 0.000 description 18
102000005962 receptors Human genes 0.000 description 18
108020003175 receptors Proteins 0.000 description 18
238000012546 transfer Methods 0.000 description 18
108700019146 Transgenes Proteins 0.000 description 17
239000003623 enhancer Substances 0.000 description 17
239000003446 ligand Substances 0.000 description 17
241001430294 unidentified retrovirus Species 0.000 description 17
108091026890 Coding region Proteins 0.000 description 16
102000004190 Enzymes Human genes 0.000 description 16
108090000790 Enzymes Proteins 0.000 description 16
229940088598 enzyme Drugs 0.000 description 16
206010059866 Drug resistance Diseases 0.000 description 15
241000588724 Escherichia coli Species 0.000 description 15
235000001014 amino acid Nutrition 0.000 description 15
201000011510 cancer Diseases 0.000 description 15
238000013518 transcription Methods 0.000 description 15
230000035897 transcription Effects 0.000 description 15
241000713772 Human immunodeficiency virus 1 Species 0.000 description 14
VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 14
210000001185 bone marrow Anatomy 0.000 description 14
230000001413 cellular effect Effects 0.000 description 14
230000006870 function Effects 0.000 description 14
230000001177 retroviral effect Effects 0.000 description 14
241000725303 Human immunodeficiency virus Species 0.000 description 13
210000000349 chromosome Anatomy 0.000 description 13
230000003834 intracellular effect Effects 0.000 description 13
150000001413 amino acids Chemical class 0.000 description 12
239000003471 mutagenic agent Substances 0.000 description 12
230000001225 therapeutic effect Effects 0.000 description 12
238000011282 treatment Methods 0.000 description 12
108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
241000701022 Cytomegalovirus Species 0.000 description 11
101710096438 DNA-binding protein Proteins 0.000 description 11
108091028043 Nucleic acid sequence Proteins 0.000 description 11
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
229940100198 alkylating agent Drugs 0.000 description 11
239000002168 alkylating agent Substances 0.000 description 11
238000004520 electroporation Methods 0.000 description 11
244000005700 microbiome Species 0.000 description 11
230000004224 protection Effects 0.000 description 11
230000001105 regulatory effect Effects 0.000 description 11
241000894007 species Species 0.000 description 11
101000574227 Homo sapiens Methylated-DNA-protein-cysteine methyltransferase Proteins 0.000 description 10
241001135569 Human adenovirus 5 Species 0.000 description 10
210000004369 blood Anatomy 0.000 description 10
239000008280 blood Substances 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
230000002759 chromosomal effect Effects 0.000 description 10
210000003958 hematopoietic stem cell Anatomy 0.000 description 10
102000057149 human MGMT Human genes 0.000 description 10
230000003993 interaction Effects 0.000 description 10
239000002502 liposome Substances 0.000 description 10
238000003199 nucleic acid amplification method Methods 0.000 description 10
239000013607 AAV vector Substances 0.000 description 9
125000000217 alkyl group Chemical group 0.000 description 9
230000001580 bacterial effect Effects 0.000 description 9
239000002299 complementary DNA Substances 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
239000000835 fiber Substances 0.000 description 9
210000004962 mammalian cell Anatomy 0.000 description 9
238000004519 manufacturing process Methods 0.000 description 9
239000007858 starting material Substances 0.000 description 9
239000000126 substance Substances 0.000 description 9
238000010361 transduction Methods 0.000 description 9
230000026683 transduction Effects 0.000 description 9
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 8
102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 8
108010043121 Green Fluorescent Proteins Proteins 0.000 description 8
108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
125000003275 alpha amino acid group Chemical group 0.000 description 8
230000003321 amplification Effects 0.000 description 8
238000003780 insertion Methods 0.000 description 8
230000037431 insertion Effects 0.000 description 8
239000000203 mixture Substances 0.000 description 8
102000040430 polynucleotide Human genes 0.000 description 8
108091033319 polynucleotide Proteins 0.000 description 8
239000002157 polynucleotide Substances 0.000 description 8
101150003532 CSH gene Proteins 0.000 description 7
230000004568 DNA-binding Effects 0.000 description 7
102000004144 Green Fluorescent Proteins Human genes 0.000 description 7
241000699670 Mus sp. Species 0.000 description 7
238000000137 annealing Methods 0.000 description 7
230000000840 anti-viral effect Effects 0.000 description 7
238000013459 approach Methods 0.000 description 7
238000011161 development Methods 0.000 description 7
230000018109 developmental process Effects 0.000 description 7
201000010099 disease Diseases 0.000 description 7
239000005090 green fluorescent protein Substances 0.000 description 7
239000013600 plasmid vector Substances 0.000 description 7
108020005544 Antisense RNA Proteins 0.000 description 6
241000894006 Bacteria Species 0.000 description 6
108700020911 DNA-Binding Proteins Proteins 0.000 description 6
101001040800 Homo sapiens Integral membrane protein GPR180 Proteins 0.000 description 6
102100021244 Integral membrane protein GPR180 Human genes 0.000 description 6
210000001744 T-lymphocyte Anatomy 0.000 description 6
239000002246 antineoplastic agent Substances 0.000 description 6
238000002512 chemotherapy Methods 0.000 description 6
239000003184 complementary RNA Substances 0.000 description 6
230000021615 conjugation Effects 0.000 description 6
230000006698 induction Effects 0.000 description 6
230000002458 infectious effect Effects 0.000 description 6
210000005265 lung cell Anatomy 0.000 description 6
238000012423 maintenance Methods 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
230000000306 recurrent effect Effects 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
102000014914 Carrier Proteins Human genes 0.000 description 5
230000004543 DNA replication Effects 0.000 description 5
UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 5
108091061960 Naked DNA Proteins 0.000 description 5
239000002202 Polyethylene glycol Substances 0.000 description 5
241000700159 Rattus Species 0.000 description 5
108091008324 binding proteins Proteins 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
210000000234 capsid Anatomy 0.000 description 5
238000004113 cell culture Methods 0.000 description 5
231100000433 cytotoxic Toxicity 0.000 description 5
230000001472 cytotoxic effect Effects 0.000 description 5
230000006378 damage Effects 0.000 description 5
108020001507 fusion proteins Proteins 0.000 description 5
102000037865 fusion proteins Human genes 0.000 description 5
230000012010 growth Effects 0.000 description 5
210000005260 human cell Anatomy 0.000 description 5
238000010348 incorporation Methods 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
238000002955 isolation Methods 0.000 description 5
239000000463 material Substances 0.000 description 5
210000004940 nucleus Anatomy 0.000 description 5
230000001717 pathogenic effect Effects 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
230000001681 protective effect Effects 0.000 description 5
101150066583 rep gene Proteins 0.000 description 5
210000002845 virion Anatomy 0.000 description 5
XWNJMSJGJFSGRY-UHFFFAOYSA-N 2-(benzylamino)-3,7-dihydropurin-6-one Chemical compound N1C=2N=CNC=2C(=O)N=C1NCC1=CC=CC=C1 XWNJMSJGJFSGRY-UHFFFAOYSA-N 0.000 description 4
108091023037 Aptamer Proteins 0.000 description 4
108010006654 Bleomycin Proteins 0.000 description 4
108090000994 Catalytic RNA Proteins 0.000 description 4
102000053642 Catalytic RNA Human genes 0.000 description 4
108010001857 Cell Surface Receptors Proteins 0.000 description 4
102000000844 Cell Surface Receptors Human genes 0.000 description 4
241000702421 Dependoparvovirus Species 0.000 description 4
101710145505 Fiber protein Proteins 0.000 description 4
241000724791 Filamentous phage Species 0.000 description 4
108091006027 G proteins Proteins 0.000 description 4
102000030782 GTP binding Human genes 0.000 description 4
108091000058 GTP-Binding Proteins 0.000 description 4
102000004862 Gastrin releasing peptide Human genes 0.000 description 4
108090001053 Gastrin releasing peptide Proteins 0.000 description 4
108700028146 Genetic Enhancer Elements Proteins 0.000 description 4
241000282412 Homo Species 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
101710149951 Protein Tat Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
241000711975 Vesicular stomatitis virus Species 0.000 description 4
108700005077 Viral Genes Proteins 0.000 description 4
238000005804 alkylation reaction Methods 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000008901 benefit Effects 0.000 description 4
229960001561 bleomycin Drugs 0.000 description 4
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 4
239000013611 chromosomal DNA Substances 0.000 description 4
229960001338 colchicine Drugs 0.000 description 4
238000010276 construction Methods 0.000 description 4
230000002950 deficient Effects 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
238000001638 lipofection Methods 0.000 description 4
230000007774 longterm Effects 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
102000044158 nucleic acid binding protein Human genes 0.000 description 4
108700020942 nucleic acid binding protein Proteins 0.000 description 4
238000004091 panning Methods 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
244000052769 pathogen Species 0.000 description 4
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 4
108091092562 ribozyme Proteins 0.000 description 4
208000011580 syndromic disease Diseases 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
230000010415 tropism Effects 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
206010065553 Bone marrow failure Diseases 0.000 description 3
101150029409 CFTR gene Proteins 0.000 description 3
108010051219 Cre recombinase Proteins 0.000 description 3
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 3
108091029865 Exogenous DNA Proteins 0.000 description 3
108010070675 Glutathione transferase Proteins 0.000 description 3
102000005720 Glutathione transferase Human genes 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
101100513188 Homo sapiens MGMT gene Proteins 0.000 description 3
108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 description 3
241000598171 Human adenovirus sp. Species 0.000 description 3
102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
102000018697 Membrane Proteins Human genes 0.000 description 3
108010052285 Membrane Proteins Proteins 0.000 description 3
101150042248 Mgmt gene Proteins 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
238000012408 PCR amplification Methods 0.000 description 3
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
108010006785 Taq Polymerase Proteins 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
230000029936 alkylation Effects 0.000 description 3
230000000692 anti-sense effect Effects 0.000 description 3
229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 3
210000002798 bone marrow cell Anatomy 0.000 description 3
238000012219 cassette mutagenesis Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
238000010367 cloning Methods 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
229940127089 cytotoxic agent Drugs 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
230000029087 digestion Effects 0.000 description 3
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
229960005420 etoposide Drugs 0.000 description 3
210000003527 eukaryotic cell Anatomy 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000000284 extract Substances 0.000 description 3
108091006047 fluorescent proteins Proteins 0.000 description 3
102000034287 fluorescent proteins Human genes 0.000 description 3
230000009395 genetic defect Effects 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
230000002018 overexpression Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
230000000644 propagated effect Effects 0.000 description 3
101150079601 recA gene Proteins 0.000 description 3
230000008439 repair process Effects 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
230000001052 transient effect Effects 0.000 description 3
241001529453 unidentified herpesvirus Species 0.000 description 3
230000029812 viral genome replication Effects 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
210000000605 viral structure Anatomy 0.000 description 3
239000011701 zinc Substances 0.000 description 3
OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 2
108700026758 Adenovirus hexon capsid Proteins 0.000 description 2
108700028369 Alleles Proteins 0.000 description 2
102000007299 Amphiregulin Human genes 0.000 description 2
108010033760 Amphiregulin Proteins 0.000 description 2
206010003591 Ataxia Diseases 0.000 description 2
241000193830 Bacillus <bacterium> Species 0.000 description 2
206010051779 Bone marrow toxicity Diseases 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
101150044789 Cap gene Proteins 0.000 description 2
101710132601 Capsid protein Proteins 0.000 description 2
206010010144 Completed suicide Diseases 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
201000003883 Cystic fibrosis Diseases 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
230000033616 DNA repair Effects 0.000 description 2
102100024746 Dihydrofolate reductase Human genes 0.000 description 2
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
208000024720 Fabry Disease Diseases 0.000 description 2
208000031886 HIV Infections Diseases 0.000 description 2
101000702718 Homo sapiens Phosphatidylcholine:ceramide cholinephosphotransferase 1 Proteins 0.000 description 2
241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
102100034349 Integrase Human genes 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
102000016397 Methyltransferase Human genes 0.000 description 2
108060004795 Methyltransferase Proteins 0.000 description 2
101100191385 Mus musculus Prkdc gene Proteins 0.000 description 2
SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 2
102000004316 Oxidoreductases Human genes 0.000 description 2
108090000854 Oxidoreductases Proteins 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
239000004365 Protease Substances 0.000 description 2
101710149136 Protein Vpr Proteins 0.000 description 2
102000044126 RNA-Binding Proteins Human genes 0.000 description 2
108700020471 RNA-Binding Proteins Proteins 0.000 description 2
108010039491 Ricin Proteins 0.000 description 2
206010042566 Superinfection Diseases 0.000 description 2
108010022394 Threonine synthase Proteins 0.000 description 2
102000004357 Transferases Human genes 0.000 description 2
108090000992 Transferases Proteins 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
108020000999 Viral RNA Proteins 0.000 description 2
230000009471 action Effects 0.000 description 2
239000012190 activator Substances 0.000 description 2
230000032683 aging Effects 0.000 description 2
230000002152 alkylating effect Effects 0.000 description 2
230000000735 allogeneic effect Effects 0.000 description 2
230000004075 alteration Effects 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
210000001106 artificial yeast chromosome Anatomy 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
231100000366 bone marrow toxicity Toxicity 0.000 description 2
230000000711 cancerogenic effect Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
229940044683 chemotherapy drug Drugs 0.000 description 2
238000009104 chemotherapy regimen Methods 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000001332 colony forming effect Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000013467 fragmentation Methods 0.000 description 2
238000006062 fragmentation reaction Methods 0.000 description 2
230000004927 fusion Effects 0.000 description 2
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
102000006495 integrins Human genes 0.000 description 2
108010044426 integrins Proteins 0.000 description 2
229930027917 kanamycin Natural products 0.000 description 2
229960000318 kanamycin Drugs 0.000 description 2
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
229930182823 kanamycin A Natural products 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
230000004807 localization Effects 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000219 mutagenic Toxicity 0.000 description 2
230000003505 mutagenic effect Effects 0.000 description 2
229960000951 mycophenolic acid Drugs 0.000 description 2
230000001338 necrotic effect Effects 0.000 description 2
210000005170 neoplastic cell Anatomy 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000008520 organization Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
238000002823 phage display Methods 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
230000007505 plaque formation Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
238000011084 recovery Methods 0.000 description 2
238000009256 replacement therapy Methods 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
238000010839 reverse transcription Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
230000007017 scission Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000012421 spiking Methods 0.000 description 2
230000010473 stable expression Effects 0.000 description 2
230000008685 targeting Effects 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000032258 transport Effects 0.000 description 2
241000712461 unidentified influenza virus Species 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
229960004528 vincristine Drugs 0.000 description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
ABSNGNUGFQIDDO-UHFFFAOYSA-N 2-benzylguanidine Chemical compound NC(N)=NCC1=CC=CC=C1 ABSNGNUGFQIDDO-UHFFFAOYSA-N 0.000 description 1
CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 description 1
XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 description 1
101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 1
208000010370 Adenoviridae Infections Diseases 0.000 description 1
206010060931 Adenovirus infection Diseases 0.000 description 1
208000008190 Agammaglobulinemia Diseases 0.000 description 1
206010001557 Albinism Diseases 0.000 description 1
108010053754 Aldehyde reductase Proteins 0.000 description 1
102100027265 Aldo-keto reductase family 1 member B1 Human genes 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
229940122998 Alkyltransferase inhibitor Drugs 0.000 description 1
108091023043 Alu Element Proteins 0.000 description 1
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
240000005220 Bischofia javanica Species 0.000 description 1
235000010893 Bischofia javanica Nutrition 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
101000709520 Chlamydia trachomatis serovar L2 (strain 434/Bu / ATCC VR-902B) Atypical response regulator protein ChxR Proteins 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
108010077544 Chromatin Proteins 0.000 description 1
241000581364 Clinitrachus argentatus Species 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
108700010070 Codon Usage Proteins 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
208000027205 Congenital disease Diseases 0.000 description 1
102000012437 Copper-Transporting ATPases Human genes 0.000 description 1
241000711573 Coronaviridae Species 0.000 description 1
241000709687 Coxsackievirus Species 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010078339 DNA alkyltransferase Proteins 0.000 description 1
238000007400 DNA extraction Methods 0.000 description 1
230000008265 DNA repair mechanism Effects 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
101710116602 DNA-Binding protein G5P Proteins 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
241000725619 Dengue virus Species 0.000 description 1
108010082610 Deoxyribonuclease (Pyrimidine Dimer) Proteins 0.000 description 1
102000007260 Deoxyribonuclease I Human genes 0.000 description 1
108010008532 Deoxyribonuclease I Proteins 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
102000018386 EGF Family of Proteins Human genes 0.000 description 1
108010066486 EGF Family of Proteins Proteins 0.000 description 1
241001466953 Echovirus Species 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
102100037696 Endonuclease V Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
101800001467 Envelope glycoprotein E2 Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
241001524679 Escherichia virus M13 Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
241000710831 Flavivirus Species 0.000 description 1
208000001914 Fragile X syndrome Diseases 0.000 description 1
208000027472 Galactosemias Diseases 0.000 description 1
108010001515 Galectin 4 Proteins 0.000 description 1
102100039556 Galectin-4 Human genes 0.000 description 1
208000015872 Gaucher disease Diseases 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
108010002459 HIV Integrase Proteins 0.000 description 1
108090001102 Hammerhead ribozyme Proteins 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
208000018565 Hemochromatosis Diseases 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
208000009292 Hemophilia A Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
102000006947 Histones Human genes 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
101001109800 Homo sapiens Pro-neuregulin-1, membrane-bound isoform Proteins 0.000 description 1
241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
108010061833 Integrases Proteins 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
108010025815 Kanamycin Kinase Proteins 0.000 description 1
241000588748 Klebsiella Species 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
241000589248 Legionella Species 0.000 description 1
208000007764 Legionnaires' Disease Diseases 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
206010024238 Leptospirosis Diseases 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
208000016604 Lyme disease Diseases 0.000 description 1
108700041567 MDR Genes Proteins 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
241000343235 Maso Species 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
241000713869 Moloney murine leukemia virus Species 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
206010048723 Multiple-drug resistance Diseases 0.000 description 1
241000711386 Mumps virus Species 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
241000711408 Murine respirovirus Species 0.000 description 1
101100236342 Mus musculus Lyst gene Proteins 0.000 description 1
108010021466 Mutant Proteins Proteins 0.000 description 1
102000008300 Mutant Proteins Human genes 0.000 description 1
241000186359 Mycobacterium Species 0.000 description 1
241001553014 Myrsine salicina Species 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 1
102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 1
102400000058 Neuregulin-1 Human genes 0.000 description 1
108090000556 Neuregulin-1 Proteins 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
108020004485 Nonsense Codon Proteins 0.000 description 1
108091093105 Nuclear DNA Proteins 0.000 description 1
102000007399 Nuclear hormone receptor Human genes 0.000 description 1
108020005497 Nuclear hormone receptor Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
241000282376 Panthera tigris Species 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
101710173835 Penton protein Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
241000701980 Phage 434 Species 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
201000011252 Phenylketonuria Diseases 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
241000288906 Primates Species 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
241000588769 Proteus <enterobacteria> Species 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 1
108091008103 RNA aptamers Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
241000711798 Rabies lyssavirus Species 0.000 description 1
102000001218 Rec A Recombinases Human genes 0.000 description 1
108010055016 Rec A Recombinases Proteins 0.000 description 1
108700005079 Recessive Genes Proteins 0.000 description 1
102000052708 Recessive Genes Human genes 0.000 description 1
108010091086 Recombinases Proteins 0.000 description 1
102000018120 Recombinases Human genes 0.000 description 1
208000035415 Reinfection Diseases 0.000 description 1
101710162453 Replication factor A Proteins 0.000 description 1
101710176758 Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
241000606701 Rickettsia Species 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
101710176276 SSB protein Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000282695 Saimiri Species 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
101100355586 Schizosaccharomyces pombe (strain 972 / ATCC 24843) rhp51 gene Proteins 0.000 description 1
241000509404 Scorpaenichthys marmoratus Species 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
241000710960 Sindbis virus Species 0.000 description 1
101710126859 Single-stranded DNA-binding protein Proteins 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
208000003028 Stuttering Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
101800001271 Surface protein Proteins 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
206010043189 Telangiectasia Diseases 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
101710183280 Topoisomerase Proteins 0.000 description 1
108010068068 Transcription Factor TFIIIA Proteins 0.000 description 1
102100028509 Transcription factor IIIA Human genes 0.000 description 1
102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
101800004564 Transforming growth factor alpha Proteins 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
108010065667 Viral Matrix Proteins Proteins 0.000 description 1
208000018839 Wilson disease Diseases 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
229920002494 Zein Polymers 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
208000011589 adenoviridae infectious disease Diseases 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
206010001689 alkaptonuria Diseases 0.000 description 1
208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002155 anti-virotic effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
230000009876 antimalignant effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000004019 antithrombin Substances 0.000 description 1
101150010487 are gene Proteins 0.000 description 1
238000003491 array Methods 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
208000005980 beta thalassemia Diseases 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000003139 biocide Substances 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
210000004900 c-terminal fragment Anatomy 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000003560 cancer drug Substances 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
231100000357 carcinogen Toxicity 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
-1 cationic lipids Chemical class 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000011748 cell maturation Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
230000006800 cellular catabolic process Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
239000004568 cement Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
230000009920 chelation Effects 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
238000003508 chemical denaturation Methods 0.000 description 1
230000001767 chemoprotection Effects 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
210000003483 chromatin Anatomy 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
230000035602 clotting Effects 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000009096 combination chemotherapy Methods 0.000 description 1
238000004891 communication Methods 0.000 description 1
238000005094 computer simulation Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
239000008380 degradant Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
201000010064 diabetes insipidus Diseases 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000009510 drug design Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000005293 duran Substances 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000000799 fusogenic effect Effects 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
210000000777 hematopoietic system Anatomy 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000005745 host immune response Effects 0.000 description 1
102000055650 human NRG1 Human genes 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000000642 iatrogenic effect Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000008676 import Effects 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
239000000411 inducer Substances 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
230000005865 ionizing radiation Effects 0.000 description 1
230000003447 ipsilateral effect Effects 0.000 description 1
239000004407 iron oxides and hydroxides Substances 0.000 description 1
101150109249 lacI gene Proteins 0.000 description 1
230000003902 lesion Effects 0.000 description 1
238000012917 library technology Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
210000002418 meninge Anatomy 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
239000012022 methylating agents‎ Substances 0.000 description 1
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
244000000010 microbial pathogen Species 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
241000264288 mixed libraries Species 0.000 description 1
102000035118 modified proteins Human genes 0.000 description 1
108091005573 modified proteins Proteins 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000009126 molecular therapy Methods 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
201000006938 muscular dystrophy Diseases 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
244000309711 non-enveloped viruses Species 0.000 description 1
230000037434 nonsense mutation Effects 0.000 description 1
230000030648 nucleus localization Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
210000004976 peripheral blood cell Anatomy 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
230000004983 pleiotropic effect Effects 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
239000002574 poison Substances 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
208000015768 polyposis Diseases 0.000 description 1
238000011176 pooling Methods 0.000 description 1
239000013641 positive control Substances 0.000 description 1
GUUBJKMBDULZTE-UHFFFAOYSA-M potassium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[K+].OCCN1CCN(CCS(O)(=O)=O)CC1 GUUBJKMBDULZTE-UHFFFAOYSA-M 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000036316 preload Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
210000004986 primary T-cell Anatomy 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000001566 pro-viral effect Effects 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000001902 propagating effect Effects 0.000 description 1
229940048914 protamine Drugs 0.000 description 1
230000006916 protein interaction Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
229950010131 puromycin Drugs 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000032537 response to toxin Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000012552 review Methods 0.000 description 1
102220068533 rs148345688 Human genes 0.000 description 1
201000005404 rubella Diseases 0.000 description 1
208000011571 secondary malignant neoplasm Diseases 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
208000002491 severe combined immunodeficiency Diseases 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
230000011664 signaling Effects 0.000 description 1
230000037432 silent mutation Effects 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
238000002791 soaking Methods 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000009331 sowing Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
208000010648 susceptibility to HIV infection Diseases 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
208000009056 telangiectasis Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
230000005100 tissue tropism Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
101150069263 tra gene Proteins 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
108091008023 transcriptional regulators Proteins 0.000 description 1
230000002463 transducing effect Effects 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000017105 transposition Effects 0.000 description 1
230000013819 transposition, DNA-mediated Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000005909 tumor killing Effects 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000035899 viability Effects 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
230000006648 viral gene expression Effects 0.000 description 1
230000017613 viral reproduction Effects 0.000 description 1
239000000277 virosome Substances 0.000 description 1
230000001018 virulence Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229940093612 zein Drugs 0.000 description 1
239000005019 zein Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14141—Use of virus, viral particle or viral elements as a vector
- C12N2795/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Crystallography & Structural Chemistry (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Public Health (AREA)
Plant Pathology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Computational Biology (AREA)
Virology (AREA)
Ecology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)

JP51594198A 1996-09-27 1997-09-26 回帰的配列シャフリングおよび選択による遺伝子治療の最適化のための方法 Pending JP2001504325A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US72266096A	1996-09-27	1996-09-27
US3774296P	1996-09-27	1996-09-27
US60/037,742		1996-09-27
US08/722,660		1996-09-27
PCT/US1997/017300 WO1998013487A1 (fr)	1996-09-27	1997-09-26	Procedes permettant l'optimisation d'une therapie genique grace a un rearrangement et une selection recursifs de sequences

Publications (1)

Publication Number	Publication Date
JP2001504325A true JP2001504325A (ja)	2001-04-03

Family

ID=26714441

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP51594198A Pending JP2001504325A (ja)	1996-09-27	1997-09-26	回帰的配列シャフリングおよび選択による遺伝子治療の最適化のための方法

Country Status (5)

Country	Link
EP (1)	EP0964922A4 (fr)
JP (1)	JP2001504325A (fr)
AU (1)	AU4503797A (fr)
CA (1)	CA2266423A1 (fr)
WO (1)	WO1998013487A1 (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6309883B1 (en)	1994-02-17	2001-10-30	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
US20060257890A1 (en)	1996-05-20	2006-11-16	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
US6713279B1 (en)	1995-12-07	2004-03-30	Diversa Corporation	Non-stochastic generation of genetic vaccines and enzymes
WO2000053744A2 (fr) *	1999-03-09	2000-09-14	Diversa Corporation	Selection finale d'une evolution dirigee
US6939689B2 (en)	1995-12-07	2005-09-06	Diversa Corporation	Exonuclease-mediated nucleic acid reassembly in directed evolution
US6358709B1 (en)	1995-12-07	2002-03-19	Diversa Corporation	End selection in directed evolution
US6238884B1 (en)	1995-12-07	2001-05-29	Diversa Corporation	End selection in directed evolution
US6740506B2 (en)	1995-12-07	2004-05-25	Diversa Corporation	End selection in directed evolution
US5830696A (en)	1996-12-05	1998-11-03	Diversa Corporation	Directed evolution of thermophilic enzymes
CA2276064C (fr)	1997-01-17	2013-12-17	Maxygen, Inc.	Evolution de cellules entieres et d'organismes par recombinaison recursive de sequences
US6326204B1 (en)	1997-01-17	2001-12-04	Maxygen, Inc.	Evolution of whole cells and organisms by recursive sequence recombination
US6602677B1 (en) *	1997-09-19	2003-08-05	Promega Corporation	Thermostable luciferases and methods of production
AU1124499A (en)	1997-10-28	1999-05-17	Maxygen, Inc.	Human papillomavirus vectors
WO1999023107A1 (fr)	1997-10-31	1999-05-14	Maxygen, Incorporated	Modification du tropisme viral et de la diversite d'especes hote par recombinaison du genome viral
US6426185B1 (en)	1998-01-16	2002-07-30	Large Scale Biology Corporation	Method of compiling a functional gene profile in a plant by transfecting a nucleic acid sequence of a donor plant into a different host plant in an anti-sense orientation
US6468745B1 (en)	1998-01-16	2002-10-22	Large Scale Biology Corporation	Method for expressing a library of nucleic acid sequence variants and selecting desired traits
US6303848B1 (en)	1998-01-16	2001-10-16	Large Scale Biology Corporation	Method for conferring herbicide, pest, or disease resistance in plant hosts
WO1999057128A1 (fr)	1998-05-01	1999-11-11	Maxygen, Inc.	Optimisation de genes de resistance aux ravageurs par rearrangement d'adn
WO1999065927A2 (fr)	1998-06-17	1999-12-23	Maxygen, Inc.	Technique de production de polynucleotides aux caracteristiques souhaitees
WO2000009682A1 (fr)	1998-08-12	2000-02-24	Maxygen, Inc.	Rearrangement d'adn de genes de monoxygenase en vue de la production de produits chimiques industriels
WO2000020573A2 (fr)	1998-10-07	2000-04-13	Maxygen, Inc.	Rearrangement d'adn pour produire des acides nucleiques de detoxication contre les mycotoxines
GB9823468D0 (en)	1998-10-28	1998-12-23	Secr Defence	Novel enzyme
WO2000028018A1 (fr)	1998-11-10	2000-05-18	Maxygen, Inc.	Adp-glucose pyrophosphorylase modifiee pour l'amelioration et l'optimisation de phenotypes vegetaux
US6358712B1 (en)	1999-01-05	2002-03-19	Trustee Of Boston University	Ordered gene assembly
US6436675B1 (en)	1999-09-28	2002-08-20	Maxygen, Inc.	Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6376246B1 (en)	1999-02-05	2002-04-23	Maxygen, Inc.	Oligonucleotide mediated nucleic acid recombination
US6917882B2 (en)	1999-01-19	2005-07-12	Maxygen, Inc.	Methods for making character strings, polynucleotides and polypeptides having desired characteristics
IL138002A0 (en)	1999-01-19	2001-10-31	Maxygen Inc	Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6961664B2 (en)	1999-01-19	2005-11-01	Maxygen	Methods of populating data structures for use in evolutionary simulations
US7024312B1 (en)	1999-01-19	2006-04-04	Maxygen, Inc.	Methods for making character strings, polynucleotides and polypeptides having desired characteristics
CA2361384A1 (fr)	1999-02-11	2000-08-17	Sun Ai Raillard	Spectrometrie de masse a haut rendement
US6531316B1 (en)	1999-03-05	2003-03-11	Maxyag, Inc.	Encryption of traits using split gene sequences and engineered genetic elements
IL147563A0 (en)	1999-08-12	2002-08-14	Pfizer Prod Inc	Streptomyces avermitilis gene directing the ratio of b2:b1 avermectins
US7430477B2 (en)	1999-10-12	2008-09-30	Maxygen, Inc.	Methods of populating data structures for use in evolutionary simulations
GB9925161D0 (en)	1999-10-26	1999-12-22	Secr Defence	Novel enzyme
AU1800401A (en) *	1999-11-23	2001-06-04	Maxygen, Inc.	Shuffling of agrobacterium and viral genes, plasmids and genomes for improved plant transformation
US6686515B1 (en)	1999-11-23	2004-02-03	Maxygen, Inc.	Homologous recombination in plants
US7115712B1 (en)	1999-12-02	2006-10-03	Maxygen, Inc.	Cytokine polypeptides
WO2001059071A2 (fr)	2000-02-09	2001-08-16	Genvec, Inc.	Methodes de preparation et d'utilisation d'une bibliotheque de vecteurs viraux
DK1254238T3 (da)	2000-02-09	2009-11-30	Basf Se	Nyt elongasegen og fremgangsmåde til fremstilling af flerumættede fedtsyrer
US20010049104A1 (en) *	2000-03-24	2001-12-06	Stemmer Willem P.C.	Methods for modulating cellular and organismal phenotypes
CN1328144A (zh) *	2000-06-12	2001-12-26	上海博德基因开发有限公司	一种新的多肽——甲基化－dna－蛋白－半胱氨酸甲基转移酶10和编码这种多肽的多核苷酸
AU2001268716A1 (en)	2000-06-23	2002-01-08	Maxygen, Inc.	Novel chimeric promoters
JP2004513878A (ja)	2000-06-23	2004-05-13	マキシジェン，　インコーポレイテッド	新規同時刺激分子
US6858422B2 (en)	2000-07-13	2005-02-22	Codexis, Inc.	Lipase genes
US7879540B1 (en)	2000-08-24	2011-02-01	Promega Corporation	Synthetic nucleic acid molecule compositions and methods of preparation
DE60143959D1 (de)	2000-08-25	2011-03-10	Basf Plant Science Gmbh	En kodieren
AU2004260931B9 (en)	2003-04-29	2012-01-19	E.I. Du Pont De Nemours And Company	Novel glyphosate-N-acetyltransferase (GAT) genes
GB0107510D0 (en)	2001-03-26	2001-05-16	Univ Bristol	New elongase gene and a process for the production of -9-polyunsaturated fatty acids
US7647184B2 (en)	2001-08-27	2010-01-12	Hanall Pharmaceuticals, Co. Ltd	High throughput directed evolution by rational mutagenesis
US20030129203A1 (en) *	2001-08-27	2003-07-10	Nautilus Biotech S.A.	Mutant recombinant adeno-associated viruses
EP1539960B1 (fr)	2002-09-09	2010-04-28	Hanall Pharmaceutical Co., Ltd.	Polypeptides modifiés d'interferon alpha résistant aux protéases
US7468267B2 (en)	2003-08-25	2008-12-23	Funzyme Biotechnologies Sa	Fungal proteins and nucleic acids encoding same
EP1720981A2 (fr)	2004-03-02	2006-11-15	EPFL Ecole Polytechnique Fédérale de Lausanne	Mutants de o6-alkylguanine-adn alkyltransferase
CA2569767C (fr)	2004-06-09	2011-07-26	Pioneer Hi-Bred International, Inc.	Peptides de transit vers des plastes
US7728118B2 (en)	2004-09-17	2010-06-01	Promega Corporation	Synthetic nucleic acid molecule compositions and methods of preparation
US8715988B2 (en)	2005-03-28	2014-05-06	California Institute Of Technology	Alkane oxidation by modified hydroxylases
US7572618B2 (en)	2006-06-30	2009-08-11	Bristol-Myers Squibb Company	Polynucleotides encoding novel PCSK9 variants
EP3115459A3 (fr)	2008-05-23	2017-04-26	E. I. du Pont de Nemours and Company	Nouveaux gènes dgat permettant d'augmenter la production de lipides de stockage de semences et profils d'acides gras modifiés dans des plantes à graines oléagineuses
KR102025502B1 (ko)	2008-09-26	2019-09-25	토카겐 인크.	유전자 요법 벡터와 시토신 디아미나아제
CN102549009A (zh)	2009-08-20	2012-07-04	先锋国际良种公司	在玉蜀黍中功能性表达改组酵母硝酸盐转运蛋白(ynt1)以改善低硝酸盐环境下的硝酸盐吸收
MX2012007681A (es)	2009-12-31	2013-01-29	Pioneer Hi Bred Int	Ingenieria de resistencia de plantas a enfermedades causadas por patogenos.
AU2011289283B2 (en)	2010-08-13	2015-04-30	Pioneer Hi-Bred International, Inc.	Chimeric promoters and methods of use
BR112014027468A2 (pt)	2012-05-04	2017-06-27	Du Pont	polinucleotídeo isolado ou recombinante, construção de dna recombinante, célula, planta, explante vegetal, semente transgênica, polipeptídeo isolado, composição, métodos de produção de meganuclease, de introdução de rompimento e de integração de um polinucleotídeo.
WO2014153242A1 (fr)	2013-03-14	2014-09-25	Pioneer Hi-Bred International, Inc.	Compositions ayant une activité de décarboxylase de dicamba et leurs procédés d'utilisation
US20160053277A1 (en)	2013-03-14	2016-02-25	Pioneer Hi-Bred International, Inc.	Compositions Having Dicamba Decarboxylase Activity and Methods of Use
WO2016040788A1 (fr)	2014-09-11	2016-03-17	Promega Corporation	Substrats émettant dans l'infrarouge utilisant des séquences de luciférase pour produire une luminescence augmentée
BR112022013503A2 (pt)	2020-01-10	2022-09-13	Univ California	Plataforma biossintética para a produção de ácido olivetólico e análogos de ácido olivetólico

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6096548A (en) *	1996-03-25	2000-08-01	Maxygen, Inc.	Method for directing evolution of a virus

1997
- 1997-09-26 AU AU45037/97A patent/AU4503797A/en not_active Abandoned
- 1997-09-26 EP EP97943600A patent/EP0964922A4/fr not_active Withdrawn
- 1997-09-26 CA CA002266423A patent/CA2266423A1/fr not_active Abandoned
- 1997-09-26 JP JP51594198A patent/JP2001504325A/ja active Pending
- 1997-09-26 WO PCT/US1997/017300 patent/WO1998013487A1/fr not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP0964922A1 (fr)	1999-12-22
EP0964922A4 (fr)	2000-10-25
AU4503797A (en)	1998-04-17
CA2266423A1 (fr)	1998-04-02
WO1998013487A1 (fr)	1998-04-02

Publication	Publication Date	Title
JP2001504325A (ja)	2001-04-03	回帰的配列シャフリングおよび選択による遺伝子治療の最適化のための方法
EP0963434A1 (fr)	1999-12-15	Procedes permettant l'optimisation de la therapie genique grace a un rearrangement et une selection recursifs de sequences
US11459557B2 (en)	2022-10-04	Use and production of CHD8+/− transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
JP3681752B2 (ja)	2005-08-10	遺伝子治療に使用できる宿主 − ベクタ系
EP2401367B1 (fr)	2016-11-30	Transposases piggybac hyperactives
JP2024023194A (ja)	2024-02-21	肝臓ターゲティングおよび治療のためのＣＲＩＳＰＲ－Ｃａｓ系、ベクターおよび組成物の送達および使用
US6027722A (en)	2000-02-22	Vectors for gene transfer
US6596539B1 (en)	2003-07-22	Modification of virus tropism and host range by viral genome shuffling
AU699706B2 (en)	1998-12-10	Improved vectors for gene therapy
KR20160056869A (ko)	2016-05-20	바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
KR20160019553A (ko)	2016-02-19	유사분열 후 세포의 질병 및 장애를 표적화하고 모델링하기 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
US20020103152A1 (en)	2002-08-01	Methods of in vivo gene transfer using a sleeping beauty transposon system
KR20150105956A (ko)	2015-09-18	서열 조작 및 치료적 적용을 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
EP3237615A1 (fr)	2017-11-01	Crispr présentant ou associé avec un domaine de déstabilisation
JPH09509578A (ja)	1997-09-30	組み込み可能な組み換えアデノウィルス、それらの製造及びそれらの治療的利用
WO2016094880A1 (fr)	2016-06-16	Administration, utilisation et applications thérapeutiques de systèmes crispr et compositions pour l'édition de génome de cellules souches hématopoïétiques (hsc)
JPH10507061A (ja)	1998-07-14	アデノウイルス中にパッケージされたプラスミドｄｎａを用いる遺伝子送達ベクターおよびパッケージング細胞株
WO1996021007A2 (fr)	1996-07-11	Systemes de transfert genique a mediation par bacteriophage capables d'effectuer une transfection des cellules eucaryotiques
JPH11505128A (ja)	1999-05-18	キメラインテグラーゼタンパク質に媒介される真核生物ゲノム中へのベクター構築物の位置特異的組み込み
Boulikas	1998	Status of gene therapy in 1997: molecular mechanisms, disease targets, and clinical applications
JP2002543792A (ja)	2002-12-24	ベクターによるトランスポゾン配列の供給及び組込み
EP0716710B1 (fr)	2000-11-15	Procedes de suppression de la reponse immunitaire par therapie genique
CZ296600B6 (cs)	2006-04-12	Virový vektor obsahující replikující se DNA, zpusob prípravy této DNA a farmaceutická kompozice obsahující virový vektor
WO2020117992A9 (fr)	2020-08-20	Systèmes de vecteurs améliorés pour l'administration de protéine cas et de sgrna, et leurs utilisations
JP4159620B2 (ja)	2008-10-01	組換えアデノウイルスの製造方法